FBRX News and Press, Forte Biosciences Inc.

2024-05-13 17:16:35 ET More on Forte Biosciences Seeking Alpha’s Quant Rating on Forte Biosciences Historical earnings data for Forte Biosciences Financial information for Forte Biosciences Read the full article on Seeking Alpha For further det...

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced first quarter 2024 results and provided a business update. First Quarter 2024 Business Highlights ȁ...

2024-03-19 06:53:23 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Forte Biosciences (NASDAQ: FBRX ) just reported results for the fourth quarter of 2023. Forte Biosciences reported earnings per share of -4 cents. The company did not ...

2024-03-18 16:42:52 ET More on Forte Biosciences Seeking Alpha’s Quant Rating on Forte Biosciences Historical earnings data for Forte Biosciences Financial information for Forte Biosciences Read the full article on Seeking Alpha For further det...

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its 2023 results and provided a business update. 2023 Business Highlights “Forte achieved a major...

2023-11-14 01:45:40 ET More on Forte Biosciences Seeking Alpha’s Quant Rating on Forte Biosciences Historical earnings data for Forte Biosciences Financial information for Forte Biosciences For further details see: Forte Biosciences GAAP EPS of -$0.26

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced third quarter 2023 results and provided a business update. Third Quarter 2023 Business Highlights “The third qua...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

Forte Biosciences Inc. (FBRX) is expected to report for Q3 2023

2023-09-20 17:36:12 ET More on Forte Biosciences Forte Biosciences closes $25M financing, to advance FB-102 in 2024 Financial information for Forte Biosciences For further details see: Forte Biosciences rebuke board challengers, re-elect incumbents